[1]

Kisseleva T, Brenner D. 2021. Molecular and cellular mechanisms of liver fibrosis and its regression. Nature Reviews Gastroenterology & Hepatology 18:151−166

doi: 10.1038/s41575-020-00372-7
[2]

Hammerich L, Tacke F. 2023. Hepatic inflammatory responses in liver fibrosis. Nature Reviews Gastroenterology & Hepatology 20:633−646

doi: 10.1038/s41575-023-00807-x
[3]

Parola M, Pinzani M. 2019. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Molecular Aspects of Medicine 65:37−55

doi: 10.1016/j.mam.2018.09.002
[4]

Friedman SL, Pinzani M. 2022. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology 75:473−488

doi: 10.1002/hep.32285
[5]

Keam SJ. 2024. Resmetirom: first approval. Drugs 84:729−735

doi: 10.1007/s40265-024-02045-0
[6]

Brisnovali NF, Haney C, Goedeke L. 2024. Rezdiffra™ (resmetirom): a THR-β agonist for non-alcoholic steatohepatitis. Trends in Pharmacological Sciences 45:1081−1082

doi: 10.1016/j.tips.2024.08.009
[7]

Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, et al. 2026. Semaglutide therapy for metabolic dysfunction – associated steatohepatitis: November 2025 updates to AASLD practice guidance. Hepatology 83:1326−1340

doi: 10.1097/hep.0000000000001608
[8]

Noureddin M, Kowdley KV, Odrljin T, Bain G, Zhao J, et al. 2026. Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet 407:794−804

doi: 10.1016/s0140-6736(25)02276-7
[9]

Ni T, Li XY, Lu N, An T, Liu ZP, et al. 2016. Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer. Nature Cell Biology 18:1221−1232

doi: 10.1038/ncb3425
[10]

Wu ZQ, Rowe RG, Lim KC, Lin Y, Willis A, et al. 2014. A Snail1/Notch1 signalling axis controls embryonic vascular development. Nature Communications 5:3998

doi: 10.1038/ncomms4998
[11]

Grande MT, Sánchez-Laorden B, López-Blau C, De Frutos CA, Boutet A, et al. 2015. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nature Medicine 21:989−997

doi: 10.1038/nm.3901
[12]

Manetti M, Romano E, Rosa I, Guiducci S, Bellando-Randone S, et al. 2017. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases 76:924−934

doi: 10.1136/annrheumdis-2016-210229
[13]

Jayachandran A, Königshoff M, Yu H, Rupniewska E, Hecker M, et al. 2009. SNAI transcription factors mediate epithelial-mesenchymal transition in lung fibrosis. Thorax 64:1053−1061

doi: 10.1136/thx.2009.121798
[14]

Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, et al. 2011. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 53:1685−1695

doi: 10.1002/hep.24206
[15]

Rowe RG, Lin Y, Shimizu-Hirota R, Hanada S, Neilson EG, et al. 2011. Hepatocyte-derived Snail1 propagates liver fibrosis progression. Molecular and Cellular Biology 31:2392−2403

doi: 10.1128/mcb.01218-10
[16]

Wang P, Kang Q, Wu WS, Rui L. 2024. Hepatic Snai1 and Snai2 promote liver regeneration and suppress liver fibrosis in mice. Cell Reports 43:113875

doi: 10.1016/j.celrep.2024.113875
[17]

Bao L, Chu Y, Kang H. 2023. SNAI1-activated long non-coding RNA LINC01711 promotes hepatic fibrosis cell proliferation and migration by regulating XYLT1. Genomics 115:110597

doi: 10.1016/j.ygeno.2023.110597
[18]

Tan S, Lu Y, Xu M, Huang X, Liu H, et al. 2019. β-Arrestin1 enhances liver fibrosis through autophagy‐mediated Snail signaling. The FASEB Journal 33:2000−2016

doi: 10.1096/fj.201800828RR
[19]

Sugimoto A, Saito Y, Wang G, Sun Q, Yin C, et al. 2025. Hepatic stellate cells control liver zonation, size and functions via R-spondin 3. Nature 640:752−761

doi: 10.1038/s41586-025-08677-w
[20]

Trépo E, Goossens N, Fujiwara N, Song WM, Colaprico A, et al. 2018. Combination of gene expression signature and model for end-stage liver disease score predicts survival of patients with severe alcoholic hepatitis. Gastroenterology 154:965−975

doi: 10.1053/j.gastro.2017.10.048
[21]

Jeong BK, Choi WI, Choi W, Moon J, Lee WH, et al. 2024. A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma. Nature Communications 15:6506

doi: 10.1038/s41467-024-50660-y
[22]

Steixner-Kumar AA, Santacruz D, Geiger T, Rust W, Böttner D, et al. 2025. Single-cell landscape of peripheral immune cells in MASLD/MASH. Hepatology Communications 9:e0643

doi: 10.1097/hc9.0000000000000643
[23]

Uchinami H, Seki E, Brenner DA, D'Armiento J. 2006. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 44:420−429

doi: 10.1002/hep.21268
[24]

Wang L, Mazagova M, Pan C, Yang S, Brandl K, et al. 2019. YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. Proceedings of the National Academy of Sciences of the United States of America 116:15184−15193

doi: 10.1073/pnas.1904360116
[25]

Li ZW, Ruan B, Yang PJ, Liu JJ, Song P, et al. 2023. Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells. Signal Transduction and Targeted Therapy 8:344

doi: 10.1038/s41392-023-01621-2
[26]

Mederacke I, Dapito DH, Affò S, Uchinami H, Schwabe RF. 2015. High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nature Protocols 10:305−315

doi: 10.1038/nprot.2015.017
[27]

Pan C, Liu J, Gao Y, Yang M, Hu H, et al. 2023. Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humans. Cell Metabolism 35:2231−2249. e7

doi: 10.1016/j.cmet.2023.10.018
[28]

Gao YS, Qian MY, Wei QQ, Duan XB, Wang SL, et al. 2020. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice. Acta Pharmacologica Sinica 41:336−347

doi: 10.1038/s41401-019-0310-0
[29]

Ren B, Li Y, Di L, Cheng R, Liu L, et al. 2024. A naturally derived small molecule compound suppresses tumor growth and metastasis in mice by relieving p53-dependent repression of CDK2/Rb signaling and the Snail-driven EMT. Chinese Journal of Natural Medicines 22:112−126

doi: 10.1016/s1875-5364(24)60550-9
[30]

Ren BX, Zeng ZL, Deng L, Hu JM, Chen MZ, et al. 2025. Genetic and pharmacological targeting of Snail inhibits atherosclerosis by relieving intraplaque endothelium dysfunction and associated inflammation. Acta Pharmacologica Sinica 46:2196−2212

doi: 10.1038/s41401-025-01519-5
[31]

Geng F, Zhong Y, Su H, Lefai E, Magaki S, et al. 2023. SREBP-1 upregulates lipophagy to maintain cholesterol homeostasis in brain tumor cells. Cell Reports 42:112790

doi: 10.1016/j.celrep.2023.112790
[32]

Tao J, Wu Z, Liang Y, Wang J, Tang M, et al. 2025. Lhx2 specifically expressed in HSCs promotes liver regeneration and inhibits liver fibrosis. Hepatology 82:683−701

doi: 10.1097/hep.0000000000001201
[33]

Schwabe RF, Brenner DA. 2025. Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease. Nature Reviews Gastroenterology & Hepatology 22:481−499

doi: 10.1038/s41575-025-01068-6
[34]

Yang W, He H, Wang T, Su N, Zhang F, et al. 2021. Single-cell transcriptomic analysis reveals a hepatic stellate cell–activation roadmap and myofibroblast origin during liver fibrosis in mice. Hepatology 74:2774−2790

doi: 10.1002/hep.31987
[35]

Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. 2000. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology 2:76−83

doi: 10.1038/35000025
[36]

Singh D, Deshmukh RK, Das A. 2021. SNAI1-mediated transcriptional regulation of epithelial-to-mesenchymal transition genes in breast cancer stem cells. Cellular Signalling 87:110151

doi: 10.1016/j.cellsig.2021.110151
[37]

Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, et al. 2004. Peroxisome proliferator-activated receptor γ induces a phenotypic switch from activated to quiescent hepatic stellate cells. Journal of Biological Chemistry 279:11392−11401

doi: 10.1074/jbc.M310284200
[38]

Sharvit E, Abramovitch S, Reif S, Bruck R. 2013. Amplified inhibition of stellate cell activation pathways by PPAR-γ, RAR and RXR agonists. PLoS One 8:e76541

doi: 10.1371/journal.pone.0076541
[39]

Man S, Deng Y, Ma Y, Fu J, Bao H, et al. 2023. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5. 7 million adults in China. Gastroenterology 165:1025−1040

doi: 10.1053/j.gastro.2023.05.053
[40]

Zhao M, Wang L, Wang M, Zhou S, Lu Y, et al. 2022. Targeting fibrosis: mechanisms and clinical trials. Signal Transduction and Targeted Therapy 7:206

doi: 10.1038/s41392-022-01070-3
[41]

Parola M, Pinzani M. 2024. Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies. Molecular Aspects of Medicine 95:101231

doi: 10.1016/j.mam.2023.101231
[42]

Kumar V, Xin X, Ma J, Tan C, Osna N, et al. 2021. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Advanced Drug Delivery Reviews 176:113888

doi: 10.1016/j.addr.2021.113888
[43]

Bao Z, Zeng W, Zhang D, Wang L, Deng X, et al. 2022. SNAIL induces EMT and lung metastasis of tumours secreting CXCL2 to promote the invasion of M2-type immunosuppressed macrophages in colorectal cancer. International Journal of Biological Sciences 18:2867−2881

doi: 10.7150/ijbs.66854
[44]

Carmichael CL, Wang J, Nguyen T, Kolawole O, Benyoucef A, et al. 2020. The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1. Blood 136:957−973

doi: 10.1182/blood.2019002548
[45]

Elia I, Realini G, Di Mauro V, Borghi S, Bottoni L, et al. 2022. SNAI1 is upregulated during muscle regeneration and represses FGF21 and ATF3 expression by directly binding their promoters. The FASEB Journal 36:e22401

doi: 10.1096/fj.202200215R
[46]

Yang F, Li H, Li Y, Hao Y, Wang C, et al. 2021. Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis. International Immunopharmacology 99:108051

doi: 10.1016/j.intimp.2021.108051
[47]

Lan R, Lin J, Chen S, Lu Z, Gong Y, et al. 2025. Communication initiated by hepatocytes: the driver of HSC activation and liver fibrosis. Hepatology Communications 9:e0753

doi: 10.1097/hc9.0000000000000753
[48]

Gupta G, Khadem F, Uzonna JE. 2019. Role of hepatic stellate cell (HSC)-derived cytokines in hepatic inflammation and immunity. Cytokine 124:154542

doi: 10.1016/j.cyto.2018.09.004
[49]

Qian H, Deng X, Huang ZW, Wei J, Ding CH, et al. 2015. An HNF1α-regulated feedback circuit modulates hepatic fibrogenesis via the crosstalk between hepatocytes and hepatic stellate cells. Cell Research 25:930−945

doi: 10.1038/cr.2015.84
[50]

Tsuchida T, Friedman SL. 2017. Mechanisms of hepatic stellate cell activation. Nature Reviews Gastroenterology & Hepatology 14:397−411

doi: 10.1038/nrgastro.2017.38
[51]

Felli E, Nulan Y, Ortega-Ribera M, Fernández-Iglesias A, Gracia-Sancho J. 2026. The role of liver sinusoidal endothelial cells in liver diseases: key players in health and pathology. Journal of Hepatology 84:655−672

doi: 10.1016/j.jhep.2025.10.017
[52]

Zhou Y, Zhao D, Ma Q, Xu J, Cai Y, et al. 2025. Endothelial adenosine receptor 2A loss alleviates diabetic vascular calcification by blocking CREB1-SNAI1-driven EndMT. Pharmacological Research 221:107981

doi: 10.1016/j.phrs.2025.107981
[53]

Xu X, Tan X, Tampe B, Sanchez E, Zeisberg M, et al. 2015. Snail is a direct target of hypoxia-inducible factor 1α (HIF1α) in hypoxia-induced endothelial to mesenchymal transition of human coronary endothelial cells. Journal of Biological Chemistry 290:16653−16664

doi: 10.1074/jbc.M115.636944
[54]

Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, et al. 2008. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 48:770−781

doi: 10.1002/hep.22423
[55]

Cai Y, Li H, Liu M, Pei Y, Zheng J, et al. 2018. Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity. Hepatology 68:48−61

doi: 10.1002/hep.29777
[56]

Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, et al. 2022. A researcher’s guide to preclinical mouse NASH models. Nature Metabolism 4:1632−1649

doi: 10.1038/s42255-022-00700-y